NEW YORK – Pfizer (NYSE: PFE) closed Friday's trading session at $27.96, a modest 0.2% decline, as investors weighed the company's robust non-COVID drug performance against a lowered outlook for its pandemic-era products. The stock's slight dip belies a more significant strategic challenge: balancing the fading COVID revenue stream with the ambition of sustaining 5% core growth.
For the second quarter, Pfizer reported a 3% increase in revenue to $15.0 billion. On a currency-neutral basis, growth was a more tempered 1%. However, stripping out the contributions from Comirnaty (COVID vaccine) and Paxlovid (COVID antiviral), operational revenue surged 5%, highlighting the underlying strength of the company's core portfolio.
This bifurcation is central to Pfizer's current narrative. The company has raised the midpoint of its full-year revenue guidance by $500 million, now projecting between $60.5 billion and $62.5 billion. This upward revision was driven entirely by non-COVID products, which saw a $1.5 billion boost in projected contributions. Conversely, the COVID outlook was slashed by $1 billion, bringing the forecast for 2026 COVID-related product sales to approximately $4 billion.
The growth engine for Pfizer's non-COVID segment is a mix of recently launched and acquired products, which collectively grew 18% on an operational basis. Key contributors include the blood thinner Eliquis, the cancer drug Padcev, the heart condition treatment Vyndaqel, and the oncology therapy Lorbrena. These drugs are helping to offset the decline in COVID-related revenues, but the question remains whether this momentum can be sustained.
Financially, Pfizer reported adjusted earnings of $0.77 per share, reaffirming its full-year adjusted EPS guidance of $2.80 to $3.00. At the midpoint of this range, the stock trades at roughly 9.6 times adjusted earnings, a valuation that reflects the market's caution. The company's dividend yield stood at approximately 6.2% as of Friday's close, a figure that has become a focal point for income-focused investors.
Cash management remains conservative. Pfizer distributed $4.9 billion in dividends during the first half of the year but did not repurchase any shares. The company continues to prioritize deleveraging its balance sheet, with executives indicating that share buybacks will resume only after further debt reduction. Meanwhile, internal research and development spending totaled $5.3 billion, underscoring the company's commitment to its pipeline.
On a reported basis, Pfizer posted a net loss of $248 million for the quarter, a figure that diverges sharply from its adjusted profit due to a $4.3 billion non-cash impairment charge. This charge highlights the ongoing write-downs associated with COVID product inventory and commitments.
Looking ahead, Pfizer has received U.S. regulatory authorization for its updated COVID-19 vaccine for the 2026-27 season, developed in partnership with BioNTech. However, access and insurance coverage remain more restricted compared to the pandemic era, which could further dampen demand. The company faces several risks, including a faster-than-expected decline in COVID-related demand, patent expirations, drug-pricing regulations, and integration costs from recent acquisitions.
Investors are closely watching whether Pfizer can consistently achieve its 5% core growth target. Without clear evidence of sustained growth, the high dividend yield may continue to serve as a compensation for lack of growth rather than a catalyst for a re-rating of the stock. The market's reaction in the coming quarters will be telling.
